DataMEDS AI, Inc. (MEDS) Stock Price & Analysis
DataMEDS AI, Inc. (MEDS) — MoonshotScore 19/100 (Weak band), calculated Nov 18, 2026. Price $1.34 (+84.14%), as of the Nov 20, 2026 trading session; market cap $7.67M.
Educational signal · not a buy or sell recommendation · How to read this
DataMEDS AI, Inc. · MEDS · NASDAQ
TRxADE HEALTH, Inc. operates as a healthcare technology firm, modernizing retail pharmacy through its TRxADE marketplace for drug acquisition and its Bonum Health brand for patient-centric telehealth services.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · DataMEDS AI (MEDS)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, stalling growth and an expensive valuation, though the balance sheet is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Falling.
- quarterly revenue $3M (Q3 FY2025, quarter ended Sep 2025)
- Altman Z -7.83 · Piotroski F 2
Holding back: weak fundamentals, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 18 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 19 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.34 | |
| Change on the day | +84.14% | |
| Market capitalisation | $7.67M | — |
| Shares traded on the day | 89.98M |
Price & events
Other perspectives
Council score for DataMEDS AI (MEDS): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is DataMEDS AI (MEDS), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. DataMEDS AI, Inc. (MEDS) is listed on NASDAQ. In Q3 FY2025 it reported revenue of $3M and net income of -$34M. The market values it at $7.67M.
What do the latest results show for DataMEDS AI (MEDS)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $3M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $3M | -$34M | -$23.07 (diluted) |
| Q4 FY2025 | $2M | -$28M | — |
| Q1 FY2026 | $2M | -$8M | -$3.70 (diluted) |
| Q2 FY2026 | $2M | -$18M | -$7.13 (diluted) |
What are the financial strengths and risks for DataMEDS AI (MEDS)?
Short answer · as of
What is holding it back is weak fundamentals, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -7.83 · Piotroski F 2. Trailing ratios: ROA -82.9% · current ratio 0.14.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -7.83 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How does DataMEDS AI compare with its peers?
Short answer
DataMEDS AI's score ranks 8th of 8 in the bounded comparison shown, against 7 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $46.94 Nov 20, 2026 | $2.97B | 96 5-pillar Nov 18, 2026 | |
| $1069.43 Nov 20, 2026 | $123B | 92 5-pillar Nov 18, 2026 | |
| $272.93 Nov 20, 2026 | $63.1B | 88 5-pillar Nov 18, 2026 | |
| $339.09 Nov 20, 2026 | $64.7B | 86 5-pillar Nov 18, 2026 | |
| $83.52 Nov 20, 2026 | $9.23B | 73 5-pillar Nov 18, 2026 | |
| $49.63 Nov 20, 2026 | $2.35B | 63 5-pillar Nov 18, 2026 | |
| $0.09 Nov 19, 2026 | $6.60M | 30 5-pillar Nov 18, 2026 | |
| DataMEDS AI (MEDS) — this page | $1.34 | $7.67M | 19 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jun 22, 2026
- Transactions
- 4
- Identified insiders
- 2
- Purchases
- 0
- Sales
- 0
- Other transactions
- 4
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MEDS in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported MEDS in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about DataMEDS AI (MEDS)?
DataMEDS AI Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the MEDS research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for MEDS?
MEDS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is MEDS a good stock to buy?
Stock Expert AI does not rate MEDS buy, sell or hold. DataMEDS AI, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MEDS stock price today?
The last price recorded for DataMEDS AI, Inc. (MEDS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What revenue streams does TRxADE HEALTH, Inc. have in healthcare?
TRxADE HEALTH, Inc. generates revenue primarily through two distinct healthcare technology segments. The first stream comes from its TRxADE marketplace, which facilitates the procurement of pharmaceutical products.
What are the key factors to evaluate for MEDS?
DataMEDS AI, Inc. (MEDS) holds a MoonshotScore in the low range. Not financial advice.
How frequently does MEDS data refresh on this page?
MEDS's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MEDS's recent stock price performance?
DataMEDS AI, Inc. (MEDS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MEDS overvalued or undervalued right now?
DataMEDS AI, Inc. (MEDS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of MEDS?
Fractional-share availability for DataMEDS AI, Inc. (MEDS) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 9 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com